Tolerogenic dendritic cell therapy in type 1 diabetes; a phase 1b safety and immunological effecitivity study

2023-508558-25-01 Phase I and Phase II (Integrated) - Other Ongoing, recruiting

Start 2 Dec 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 2 sites

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ongoing, recruiting
Participants planned 10
Countries 1
Sites 2

Type 1 Diabetes

Key facts

Sponsor
Academisch Ziekenhuis Leiden
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
2 Dec 2024 → ongoing
Decision date (initial)
2024-10-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Type 1 Diabetes

VersionLevelCodeTermSystem organ class
24.0 LLT 10085412 Immune-mediated diabetes 100000004848
21.1 LLT 10012608 Diabetes mellitus insulin-dependent 10027433
20.0 PT 10012601 Diabetes mellitus 100000004861
20.0 LLT 10012609 Diabetes mellitus juvenile onset 10027433

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Academisch Ziekenhuis Leiden

Sponsor organisation
Academisch Ziekenhuis Leiden
Address
Albinusdreef 2
City
Leiden
Postcode
2333 ZA
Country
Netherlands

Scientific contact point

Organisation
Academisch Ziekenhuis Leiden
Contact name
JJ Zwaginga

Public contact point

Organisation
Academisch Ziekenhuis Leiden
Contact name
JJ Zwaginga

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 10 2
Rest of world 0

Investigational sites

Netherlands

2 sites · Ongoing, recruiting
Diabeter Nederland B.V.
Diabeter Rotterdam, Blaak 6, 3011 TA, Rotterdam
Academisch Ziekenhuis Leiden
Hematology, Albinusdreef 2, 2333 ZA, Leiden

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-12-02 2025-06-18

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-21 Netherlands Acceptable
2024-10-30
2024-10-30
2 SUBSTANTIAL MODIFICATION SM-1 2025-01-29 Netherlands Acceptable
2025-05-12
2025-05-12
3 SUBSTANTIAL MODIFICATION SM-2 2025-07-09 Netherlands Acceptable
2025-10-03
2025-10-03
4 SUBSTANTIAL MODIFICATION SM-3 2026-02-08 Netherlands Acceptable
2026-03-24
2026-03-24